# Title: Evidence that extracellular HSPB1 contributes to inflammation in alcohol associated hepatitis

- 3 Authors: Anne-Marie C Overstreet<sup>1</sup>, McKenzie Burge<sup>1</sup>, Annette Bellar<sup>1</sup>, Megan McMullen<sup>1</sup>,
- 4 Douglas Czarnecki<sup>1</sup>, Emily Huang1, Vai Pathak<sup>2</sup>, Chelsea Finney<sup>1</sup>, Raveena Vij<sup>3</sup>, Srinivasan
- 5 Dasarathy<sup>1, 4, 5, 7</sup>, Jaividhya Dasarathy<sup>6, 7</sup>, David Streem<sup>8</sup>, Nicole Welch<sup>1, 5</sup>, Daniel Rotroff<sup>2, 7</sup>,
- 6 Adam M Schmitt<sup>3</sup>, Laura E Nagy<sup>1, 4, 5, 7, 9</sup>, Jeannette S Messer<sup>1, 7, 9</sup>

#### 7 Affiliations:

- 8 <sup>1</sup>Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic,
- 9 Cleveland, OH, USA
- 10 <sup>2</sup>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA
- <sup>3</sup>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New
- 12 York.
- 13 <sup>4</sup>Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case
- 14 Western Reserve University, Cleveland, OH, USA
- 15 <sup>5</sup>Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA
- 16 <sup>6</sup>Department of Family Medicine, MetroHealth Medical Center, Case Western Reserve
- 17 University, Cleveland, OH, USA
- <sup>7</sup>Northern Ohio Alcohol Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio,
- 19 USA.
- 20 <sup>8</sup>Department of Psychiatry and Psychology, Cleveland Clinic Lutheran Hospital, Cleveland,
- 21 Ohio, USA
- 22 <sup>9</sup>Center for Microbiome and Human Health, Lerner Research Institute, Cleveland Clinic,
- 23 Cleveland, Ohio, USA.
- 24

# 25 Corresponding author:

- 26 Jeannette S Messer
- 27 E-mail: messerj3@ccf.org
- 28 **Conflict of Interest:** The authors declare no conflicts of interest.

- 29 Financial Support: NIDDK 1K08DK114713 (JSM), NIAAA Northeast Ohio Alcohol Research
- 30 Center Pilot and Feasibility Award (JSM), NIAAA Northeast Ohio Alcohol Research Center
- 31 5P50AA024333 (LEN), NIAAA Johns Hopkins Clinical Resource for Alcoholic Hepatitis
- 32 Investigation 5R24AA025017.

#### 33 Author Contributions:


- 34 Conceptualization: JSM
- 35 Methodology: JSM, AMCO, MB, DR, AMS, LEN
- 36 Investigation: AMCO, MB, AB, MM, DC, EH, VP, CF, RV, SD, JD, DS, NW
- 37 Funding acquisition: JSM
- 38 Project administration: JSM
- 39 Supervision: JSM, AMCO, DR, AMS, LEN
- 40 Writing original draft: JSM
- 41 Writing review & editing: JSM, AMCO, MB, AMS, LEN
- 42 Acknowledgements: We thank Connor Hansen for assistance with manuscript preparation. The
- 43 NIAAA funded Northeast Ohio Alcohol Research Center Clinical and Pre-clinical Cores were
- 44 instrumental to this work. We also acknowledge the assistance of the Cleveland Clinic Light
- 45 Microscopy Core in this study.
- 46 Data and materials availability: All data and code used in the analysis are available upon
- 47 request. Materials used in this study are available upon request and with completion of the
- 48 appropriate material transfer agreements.
- 49
- 50
- 51

#### 52 ABSTRACT

53 Background and aims: Alcohol-associated hepatitis (AH) is the most life-threatening form of 54 alcohol-associated liver disease (ALD). AH is characterized by severe inflammation attributed to 55 increased levels of ethanol, microbes or microbial components, and damage-associated 56 molecular pattern (DAMP) molecules in the liver. HSPB1 (Heat Shock Protein Family B (Small) 57 Member 1; also known as Hsp25/27) is a DAMP that is rapidly increased in and released from 58 cells experiencing stress, including hepatocytes. The goal of this study was to define the role of 59 HSPB1 in AH pathophysiology. 60 Methods: Serum HSPB1 was measured in a retrospective study of 184 heathy controls (HC), 61 62 heavy alcohol consumers (HA), patients with alcohol-associated cirrhosis (AC), and patients 63 with AH recruited from major hospital centers. HSPB1 was also retrospectively evaluated in 64 liver tissue from 10 HC and AH patients and an existing liver RNA-seq dataset. Finally, HSPB1 65 was investigated in a murine Lieber-DeCarli diet model of early ALD as well as cellular models 66 of ethanol stress in hepatocytes and hepatocyte-macrophage communication during ethanol 67 stress. 68 69 **Results:** Circulating HSPB1 was significantly increased in AH patients and levels positively 70 correlated with disease-severity scores. Likewise, HSPB1 was increased in the liver of patients 71 with severe AH and in the liver of ethanol-fed mice. In vitro, ethanol-stressed hepatocytes 72 released HSPB1, which then triggered TNF $\alpha$ -mediated inflammation in macrophages. Anti-73 HSPB1 antibody prevented TNF $\alpha$  release from macrophages exposed to media conditioned by 74 ethanol-stressed hepatocytes. 75 76 **Conclusions:** Our findings support investigation of HSPB1 as both a biomarker and therapeutic 77 target in ALD. Furthermore, this work demonstrates that anti-HSPB1 antibody is a rational 78 approach to targeting HSPB1 with the potential to block inflammation and protect hepatocytes,

79 80 without inactivating host defense.

# 82 GRAPHICAL ABSTRACT



KEY WORDS: alcohol-associated liver disease, Lieber-DeCarli, hepatocyte, macrophage,
TNFα, heat shock protein 25, heat shock protein 27, damage-associated molecular pattern
molecule

# 87 HIGHLIGHTS

- HSPB1 is significantly increased in serum and liver of patients with alcohol-associated
   hepatitis.
- Ethanol consumption leads to early increases in HSPB1 in the mouse liver.
- Hepatocytes subjected to ethanol stress release HSPB1 into the extracellular environment
   where it activates TNFα-mediated inflammation in macrophages.
- Anti-HSPB1 antibody blocks hepatocyte-triggered TNFα in a model of hepatocyte macrophage communication during ethanol stress.

95

#### 96 INTRODUCTION

97 Alcohol-associated liver disease (ALD) has reached a global prevalence of 4.8% and is now 98 the most common cause of death due to excessive alcohol consumption in the United States 99 (US).<sup>1, 2</sup> In the US, ALD mortality increased 23% between 2019 and 2020, and claimed an estimated 45,290 American lives in 2022.<sup>1,3</sup> ALD has also become the leading indication for 100 101 liver transplantation in the US, with a 63% increase in the number of patients listed for transplant 102 between 2007 and 2017.<sup>4, 5</sup> The term ALD broadly refers to any type of alcohol-induced liver damage and encompasses steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma.<sup>6</sup> In 103 104 general, higher levels of alcohol consumption lead to more severe disease, but transitions 105 between types of disease are unpredictable and ALD may go unrecognized until it becomes 106 severe. These factors make it imperative to understand the pathophysiology of ALD in order to 107 develop reliable diagnostics that predict risk of progression and therapies able to prevent severe 108 forms of disease.

109 Alcohol-associated hepatitis (AH) is the most severe and life-threatening manifestation of ALD.<sup>7</sup> Mortality in severe AH approaches 50% within three months of diagnosis and rises to 110 111 70% in patients that do not respond to corticosteroids.<sup>8</sup> Patients with AH present with rapid onset 112 signs of liver failure and systemic inflammation.<sup>9</sup> Liver biopsy in these patients typically reveals 113 steatosis, hepatocyte ballooning, Mallory-Denk hyaline inclusions, fibrosis, and infiltration by innate and adaptive immune cells.<sup>9</sup> The inflammatory cell infiltrate is accompanied by high 114 115 levels of pro-inflammatory cytokines such as TNF $\alpha$  (tumor necrosis factor alpha), IL-1 $\beta$ (interleukin-1 beta), and IL-6 (interleukin-6).<sup>9</sup> These factors suggest that AH is an acute 116 inflammatory disease superimposed on chronic ALD.<sup>6</sup> They also argue that targeting 117 118 inflammation could slow or reverse liver damage and decrease AH-associated mortality.

Inflammation results from both direct and indirect effects of alcohol on the liver. In the normal liver, tissue resident macrophages, called Kupffer cells, line the sinusoids and react to microbes, microbial components, and microbial products transmitted to the liver from the gastrointestinal (GI) tract.<sup>10</sup> These microbe-associated molecular pattern molecules (MAMPs) are detected by innate immune receptors on the surface or in the cytosol of macrophages and activate signaling cascades that lead to production and release of cytokines and chemokines. In the absence of alcohol, Kupffer cells are exposed to low levels of MAMPs, and inflammation is

limited in both extent and duration.<sup>11</sup> In contrast, alcohol can directly activate production and 126 release of AH-associated cytokines, such as TNFa, from Kupffer cells or macrophages recruited 127 into the liver.<sup>12</sup> Alcohol also damages the gut mucosal barrier, allowing increased translocation 128 129 of MAMPs to the liver where they activate production of the same suite of pro-inflammatory cytokines and chemokines in Kupffer cells or recruited macrophages.<sup>13</sup> Finally, ethanol stressed 130 131 hepatocytes can contribute to macrophage activation through release of damage-associated 132 molecular pattern molecules (DAMPs). DAMPs are intracellular proteins that are naturally found 133 at high levels inside cells or that are rapidly upregulated in response to stress. These danger 134 signals are actively secreted from ethanol stressed cells or released into the extracellular 135 environment secondary to cell death.<sup>14</sup> In the extracellular environment, DAMPs activate pattern 136 recognition receptors (PRR) on macrophages, which leads to production of the same cytokines 137 and chemokines that macrophages produce in response to MAMPs.<sup>15</sup> 138 One DAMP of particular interest in AH inflammation is HSPB1 (Heat Shock Protein Family

139 B (Small) Member 1; also known as Hsp25/27). HSPB1 protein levels are rapidly increased in a wide range of cells subjected to MAMPs or oxidative stress.<sup>16-18</sup> In these cells, HSPB1 directly 140 and indirectly counteracts cell damage and programmed cell death mechanisms, allowing them 141 to survive in otherwise deadly conditions.<sup>19, 20</sup> Although HSPB1 has not been systematically 142 143 evaluated in ALD, it has been implicated in alcohol-associated disease in other ways. 144 Hepatocytes are primarily responsible for ethanol metabolism in the liver and this metabolism 145 generates reactive oxygen species that accumulate and cause oxidative stress and cell damage with high or prolonged alcohol use.<sup>21</sup> There is a large body of literature demonstrating that 146 147 HSPB1 acts to prevent programmed cell death in cells experiencing oxidative stress.<sup>22</sup> A role for 148 HSPB1 in cellular responses to ethanol is further supported by studies in astrocytes, which 149 showed that ethanol challenge leads to increased HSPB1 gene expression in in these cells.<sup>23</sup> 150 Extracellular HSPB1 is of particular interest in ALD since patients with hepatocellular carcinoma have increased levels of HSPB1 and anti-HSPB1 antibodies in their blood; increases 151 152 that were linked to a history of alcohol use in some studies.<sup>24-28</sup> HSPB1 is reportedly released from stressed cells, including hepatocytes to activate PRR on adjacent cells.<sup>29-32</sup> HSPB1-153 154 mediated PRR activation then leads to production and release of the AH-associated cytokines 155 TNF $\alpha$  and IL-1 $\beta$  from macrophages.<sup>32, 33</sup>

156 These factors led us to examine HSPB1 in AH, with the goal of understanding the role that 157 this protein plays in inflammation and liver damage caused by alcohol consumption. We found 158 that patients with AH have significantly higher levels of HSPB1 in both their blood and liver 159 than liver disease free controls or patients with alcohol-associated cirrhosis (AC). This suggested 160 that increases in HSPB1 were related to the higher level of inflammation in AH. In a murine 161 model of chronic alcohol consumption (CAC), HSPB1 was increased in the liver prior to 162 significant liver damage, meaning that it does not result from inflammation. Similar to our 163 human and animal studies, HSPB1 protein was rapidly increased in and released from 164 hepatocytes stressed with ethanol in vitro. In the extracellular environment, HSPB1 promoted inflammation by triggering TNFa release from macrophages. The importance of HSPB1 in 165 ethanol-activated inflammation was reinforced by the fact that anti-HSPB1 antibody almost 166 167 completely mitigated TNFa release from macrophages treated with media conditioned by 168 ethanol stressed hepatocytes. Together, these findings establish a key role for HSPB1 in the inflammation of AH and identify it as a potential biomarker and therapeutic target for this 169 170 intractable disease.

171

#### 172 **RESULTS**

#### 173 Circulating HSPB1 is increased in ALD patients with the highest levels in severe AH.

Predicting the course of ALD in a given patient is extremely challenging. Nearly all patients consuming high levels of alcohol develop steatosis and many never progress to more severe disease.<sup>9</sup> However, patients can progress to life-threatening disease quickly and without any prior indication. This makes development of biomarkers that can identify patients at risk of progression vital in ALD. The ideal biomarker would be amenable to non-invasive monitoring, differentiate liver disease caused by alcohol use from other causes, predict risk of acute destabilization, and be targetable to prevent severe disease.

Identification of HSPB1 as a potential DAMP and biomarker of inflammation in AH led us
to retrospectively measure HSPB1 in serum from healthy controls (HC), heavy alcohol
consumers (HA), patients with AC, and patients with AH (**Table 1**). Levels of HSPB1 were
similar in the groups without liver disease (HC and HA). However, HSPB1 was significantly

185 higher in patients with ALD (AC and AH) versus those without liver disease (Fig. 1A). 186 Comparison of serum HSPB1 concentrations between AC and AH further revealed that HSPB1 187 was significantly higher in AH than AC. We next investigated relationships between disease 188 severity and HSPB1 in the ALD groups (Table 2). There was no correlation between HSPB1 and 189 disease severity in AC and no difference between HSPB1 in patients with severe versus mild-190 moderate AC (Fig. 1B, C). However, within the AH group, HSPB1 increased as disease severity 191 increased and levels of HSPB1 were significantly higher in severe versus mild-moderate disease 192 (Fig. ID, E). HSPB1 levels were not related to age or sex, despite literature describing HSPB1 as 193 an estrogen responsive gene (Fig. 1F, G).<sup>31</sup> Thus, high circulating HSPB1 is a feature of severe 194 AH.


195 Several post-translational modifications have been described for intracellular HSPB1, 196 including phosphorylation. Human HSPB1 contains three serines capable of accepting a 197 phospho-group, serine 15, serine 78, and serine 82.<sup>34</sup> Phosphorylation of these serines determines 198 oligomerization and distribution of HSPB1 inside cells, but the role of phosphorylation in 199 extracellular functions is far less clear. Serine 15 phosphorylation is associated with HSPB1 200 distribution to insoluble cell components during hydrogen peroxide induced oxidative stress, 201 making it unlikely to be found in extracellular HSPB1 during ethanol stress.<sup>18</sup> This made us 202 focus on HSPB1 phosphorylation at serines 78 and 82 in the patient blood (Table 3). Of the 203 tested samples, only 3 of 57 were positive for phosphorylated-HSPB1, two of the positive 204 samples were in the AC group and one was in the AH group (Fig. 1H). All of the samples 205 positive for phosphorylated HSPB1 were also positive for total HSPB1. This suggests that 206 extracellular HSPB1 is only rarely phosphorylated in ALD patients and so, phosphorylation is 207 not likely to be involved in its extracellular functions in AH.

# 208

Demographics	Healthy Control	High Alcohol	Alcohol-associated Cirrhosis	Alcohol-associated Hepatitis	
Total	51	41	49	43	
Age, mean, (SD), [range]	42.8, ( <u>+</u> 14.0), [21-66]	46.4, ( <u>+</u> 13.8), [21-65]	50.7, ( <u>+</u> 9.7), [31-69]	46.7, ( <u>+</u> 9.1), [29-62]	
Age in males	44.6, ( <u>+</u> 12.9), [24-63)	49.4, ( <u>+</u> 12.3), [27-65]	52.3, ( <u>+</u> 8.9), [35-69]	48.8, ( <u>+</u> 9.0), [33-62]	
Age in females	42.8, ( <u>+</u> 14.0), [21-66]	43.3, ( <u>+</u> 14.8), [21-63]	46.5, ( <u>+</u> 10.8), [31-66]	44.8, ( <u>+</u> 9.0), [29-57]	
Sex, n (%)					
Male	19 (37.3%)	21 (51.2%)	35 (71.4%)	21 (48.8%)	
Female	32 (62.7%)	20 (48.8%)	14 (28.6%)	22 (51.2%)	
Ethnicity, n (%)					
Asian	1 (2.0%)	0	1 (2.0%)	0	
Black	5 (9.8%)	18 (43.9%)	7 (14.3%)	2 (4.7%)	
Hispanic	1 (2.0%)	1 (2.4%)	0	0	
White	44 (86.7%)	21 (51.2%)	39 (79.6%)	41 (95.3%)	
Unknown	0	1 (2.4%)	2 (4.1%)	0	

209

# 210 Table 1. Patient demographics in studies of circulating HSPB1.



212

#### 213 Figure 1. Circulating HSPB1 is increased in ALD patients.

214 A, Violin plot of HSPB1 concentration in patient sera measured by ELISA. B, Linear regression of HSPB1 215 concentration and Child-Pugh score of AC patients. C, HSPB1 concentration in AC patients with mild-moderate 216 (≤8) vs. severe (>8) disease scores (Child-Pugh). **D**, Linear regression of HSPB1 concentration vs. MELD score of 217 AH patients. E, HSPB1 concentration in AH patients with mild-moderate ( $\leq 22$ ) vs. severe ( $\geq 22$ ) disease scores 218 (MELD). F, Linear regression of HSPB1 concentration vs. age in all patients. G, HSPB1 concentration in male vs. 219 female patients. H, Phosphorylated HSPB1 concentration in patient sera measured by ELISA. All data plotted as 220 mean ± SEM. A,H. Kruskal-Wallace test with a Dunn's multiple comparisons post-hoc test. B, D, F. Simple Linear 221 Regression, C, E, G. Mann-Whitney test. HC, healthy control; HA, high alcohol consumer; AC, alcohol-associated 222 cirrhosis; AH, alcohol-associated hepatitis. n.s. P > 0.05, \*  $P \le 0.05$ , \*\*  $P \le 0.01$ , \*\*\*  $P \le 0.001$ , \*\*\*\*  $P \le 0.0001$ . 223

Demographics	Alcohol-associated Cirrhosis	Alcohol-associated Hepatitis	
Total	31	43	
Age, mean, (SD), [range]	50.6, ( <u>+</u> 9.9), [31-68]	46.7, ( <u>+</u> 9.1), [29-62]	
Age in males	52.2, ( <u>+</u> 9.0), [38-68]	48.8, ( <u>+</u> 9.0), [33-62]	
Age in females	47.8, ( <u>+</u> 11.1), [31-66]	44.8, ( <u>+</u> 9.0), [29-57]	
Score	Child-Pugh	MELD	
Score, mean, (SD), [range]	8.4, ( <u>+</u> 2.2), [5-13]	25.8, ( <u>+</u> 6.5), [16-43]	
Score in males	8.5, ( <u>+</u> 2.3), [5-13]	27.5, ( <u>+</u> 7.3), [18-43]	
Score in females	8.4, ( <u>+</u> 2.2), [5-12]	24.1, ( <u>+</u> 5.2), [16-36]	
Sex, n (%)			
Male	20 (64.5%)	21 (48.8%)	
Female	11 (35.5%)	22 (51.2%)	
Ethnicity, n (%)			
Asian	0	0	
Black	1 (3.2%)	2 (4.7%)	
Hispanic	0	0	
White	30 (96.8%)	41 (95.3%)	
Unknown	0	0	

## 225

# 226 Table 2. Patient demographics and clinical data in studies of circulating HSPB1 and

# 227 disease severity.

228

Demographics	Healthy Control	High Alcohol	Alcohol-associated Cirrhosis	Alcohol-associated Hepatitis	
Total	15	12	13	17	
Age, mean, (SD), [range]	40.4, ( <u>+</u> 12.7), [23-62]	42.3, ( <u>+</u> 12.8), [24-63]	47.9, ( <u>+</u> 8.0), [35-60]	45.6, ( <u>+</u> 9.4), [30-60]	
Age in males	43.0, ( <u>+</u> 12.4), [25-62]	47.0, ( <u>+</u> 12.8), [30-63]	49.3, ( <u>+</u> 5.4), [41-56]	45.9, ( <u>+</u> 9.6), [33-60]	
Age in females	37.4, ( <u>+</u> 13.2), [23-62]	32.8, ( <u>+</u> 6.0), [24-37]	46.6, ( <u>+</u> 10.0), [35-60]	44.6, ( <u>+</u> 9.6), [30-55]	
Score			Child-Pugh	MELD	
Score, mean, (SD), [range]			8.4, ( <u>+</u> 3.4), [5-13]	22.3, ( <u>+</u> 3.9), [16-30]	
Score in males			8.7, ( <u>+</u> 2.4), [7-13]	23.4, ( <u>+</u> 4.2), [18-30]	
Score in females			8.1, ( <u>+</u> 2.5), [5-12]	21.1, ( <u>+</u> 3.2), [16-27]	
Sex, n (%)					
Male	8 (53.3%)	8 (66.7%)	6 (46.2%)	8 (47.1%)	
Female	7 (46.7%)	4 (33.3%)	7 (53.8%)	9 (52.9%)	
Ethnicity, n (%)					
Asian	0	0	0	0	
Black	2 (13.3%)	2 (16.7%)	0	0	
Hispanic	1 (6.7%)	0	0	0	
White	12 (80.0%)	9 (75.0%)	13 (100%)	17 (100%)	
Unknown	0	1 (8.3%)	0	0	

229

# 230 Table 3. Patient demographics and clinical data in studies of phosphorylated HSPB1 in

231 serum.

- 233 HSPB1 is increased in the liver of patients with AH. We next considered the source of
- 234 circulating HSPB1 in patients with severe AH. The liver is responsible for the majority of

ethanol metabolism and is subject to high levels of oxidative stress generated by the highly


reactive byproducts of this metabolism.<sup>35</sup> A large body of literature has demonstrated that

HSPB1 is cytoprotective in cells experiencing oxidative stress.<sup>36</sup> HSPB1 release from stressed

238 hepatocytes has also been reported.<sup>29</sup> This suggested that the liver was the most likely source of

circulating HSPB1 in the AH patients.

240 In the United States, very few ALD patients undergo diagnostic liver biopsy, so large 241 numbers of liver samples from these patients are difficult to obtain. We were fortunate to acquire 242 banked liver lysates from five patients with severe AH and five healthy controls (Table 4). These 243 samples were obtained during liver transplantation from patients with severe AH and healthy 244 donor livers. There was a clear difference in HSPB1 between HC and AH, with HSPB1 245 significantly higher in AH than HC (Fig. 2A, B). We also utilized existing RNA-seq datasets to 246 evaluate HSPB1 gene expression in the livers of patients with AH of varying severity or other 247 types of liver disease. In non-severe and severe AH (liver biopsies or explanted liver), HSPB1 248 gene expression was significantly higher than both HC and any other type of liver disease (Fig. 249 2C, D, E). Interestingly, metabolic dysfunction-associated steatotic liver disease (MASLD) was 250 not associated with increased HSPB1 gene expression. This is similar to reports in the literature 251 that HSPB1 in circulation does not differ between pediatric healthy controls and patients with 252 MASLD and that ballooning degeneration is associated with decreased HSPB1 gene expression and protein in livers from adult MASLD patients.<sup>37, 38</sup> Taken together, these data identify the 253 254 liver as an important source of circulating HSPB1 in AH and suggest that high levels of HSPB1 255 in the liver are linked to ALD, but not MASLD.



#### 258 Figure 2. HSPB1 is increased in the liver of patients with AH

259 A, Representative immunoblot for HSPB1 and GAPDH in HC and AH liver samples. B, HSPB1 protein 260 concentration relative to GAPDH as measured by densitometry in immunoblots represented in (A). C, HSPB1 gene 261 expression in RNA-seq analysis of liver from HC, AH, AC, MASLD, and HCV. D, Forrest plot depicting Log2 fold 262 changes in HSPB1 expression in samples described in (C). Patients with various types of liver disease were 263 compared to healthy controls. E, Forrest plot depicting Log2 fold changes in HSPB1 expression in samples 264 described in (C). Patients with various types of liver disease were compared to patients with severe AH. Data plotted 265 as mean ± SD, except C,D,E which is mean ± SEM. B. Mann-Whitney test. C, D. DeSeq2. HC, healthy control; AH 266 alcohol-associated hepatitis, MASLD, metabolic dysfunction associated with steatotic liver disease; HCV, hepatitis 267 C virus; TPM, transcripts per million. n.s. P > 0.05, \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001, \*\*\*\* P < 0.0001. 268

Demographics	Healthy Control	Alcohol- associated Hepatitis
Total	5	5
Age, mean, (SD)	45.6, ( <u>+</u> 6.7)	40.8, ( <u>+</u> 3.5)
Sex, <i>n</i> (%)		
Male	3 (60%)	3 (60%)
Female	2 (40%)	2 (40%)
Clinical Data		
Decompensation (n, (%))	N/A	5 (100%)
Sepsis ( <i>n, (</i> %))	N/A	0 (0%)
Maddrey's discriminant function	N/A	102.5 ( <u>+</u> 27.7)
Total bilirubin (mg/dL)	N/A	25.2 ( <u>+</u> 5.1)
Prothrombin time (sec)	N/A	32.4 ( <u>+</u> 5.7)

270

# Table 4. Patient demographics and clinical data for samples used for HSPB1 liver lysate immunoblot.

273

274 Chronic ethanol consumption increases HSPB1 in murine liver. HSPB1 could be increased 275 in the liver secondary to damage, or it could be contributing to damage. To distinguish between 276 these possibilities, we examined livers using a murine model of CAC. Mice were fed the Lieber-277 DeCarli liquid diet with increasing amounts of ethanol over 25 days or a calorie-matched diet supplemented with maltodextrin (Fig. 3A).<sup>39</sup> The final concentration of ethanol in this model is 278 279 6% and that concentration is maintained for one week. Controls were pair-fed, meaning that their 280 calorie intake was adjusted daily to match that of a paired ethanol-consuming mouse. This model 281 replicates early or mild ALD. We chose this model because our goal was to determine whether 282 increased liver HSPB1 results from liver damage or precedes and therefore potentially causes 283 liver pathology seen in AH.

Ethanol-fed (EtOH) mice had significantly higher levels of both HSPB1 mRNA and protein in their livers than pair-fed (Pair) controls (**Fig. 3B, C**). Immunofluorescence staining of liver sections from these mice identified weak HSPB1 staining in periportal regions and high HSPB1 staining around central veins in EtOH mice (**Fig. 3D, E**). Periportal hepatocytes are exposed to high levels of gut-derived components, including MAMPs.<sup>40</sup> Ethanol consumption, especially at high levels, damages the gut epithelium, allowing increased translocation of microbes, microbial components, or microbial products across the barrier and into the liver through portal

291 circulation.<sup>41</sup> HSPB1 production in response to MAMPs such as lipopolysaccharide and flagellin

is well-documented and is likely responsible for the weak periportal HSPB1 staining in the EtOH

293 mice.<sup>16, 17</sup> In contrast, HSPB1 staining was pronounced in pericentral hepatocytes, which are

294 primarily responsible for ethanol metabolism in the liver.<sup>42</sup> Of note, hepatocytes positive for

HSPB1 were also filled with lipid droplets and HSPB1 levels in the liver were positively

296 correlated with triglyceride levels in the blood of these mice (Fig. 3F, G). This is in keeping with

a report that HSPB1 knockout mice have lower levels of triglycerides in their blood.<sup>43</sup> The


298 presence of HSPB1 in the ethanol-stressed liver prior to damage was reinforced by the fact that

299 circulating aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were similar in

300 EtOH and Pair mice (Fig. 3H, I). Since HSPB1 is increased in the ethanol-stressed liver prior to

301 the onset of significant damage, the increased HSPB1 is more likely to be a cause of damage

than the result of damage.



#### 304

#### **Figure 3. Chronic ethanol consumption increases HSPB1 in murine liver.**

**A**, Illustration of murine model of CAC. **B**, Relative gene expression of HSPB1 in the liver of Pair and EtOH mice

307 measured by qRT-PCR. C, HSPB1 concentration in the liver of Pair and EtOH mice measured by ELISA. D&E,

308 Immunostaining for HSPB1 (yellow) and DNA (Hoechst, blue) in pair- and EtOH-fed mice. Scale bar =  $100 \ \mu m$ .

309 Images in (**D**) are focused on periportal hepatocytes and images in (**E**) are focused on pericentral hepatocytes.

310 Images are representative of 12 Pair and 11 EtOH mice. F, High-magnification image of HSPB1 (yellow) and DNA

311 (Hoechst, blue) immunofluorescence in the liver of EtOH mice. Scale bar =  $50 \mu m$ . G, Linear regression analysis of


- 312 liver HSPB1 and triglyceride levels in Pair and EtOH mice. H, AST levels in serum from Pair and EtOH mice. I,
- ALT levels in serum from Pair and EtOH mice. Data are plotted as mean  $\pm$  SD. B, C, H, I. Unpaired T-test. G.
- 314 Simple Linear Regression. CAC, chronic alcohol consumption; Pair, pair-fed mice; EtOH, ethanol-fed mice; TG,
- 315 triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase. n.s. P > 0.05, \*  $P \le 0.05$ , \*\*  $P \le 0.0$

 $316 \quad 0.01, *** P \le 0.001, **** P \le 0.0001.$ 

318

319 Ethanol stressed hepatocytes release HSPB1 into the extracellular environment. Findings 320 from patients and mice chronically consuming alcohol identified the liver, and specifically 321 hepatocytes, as the likely source of circulating HSPB1 in AH. To verify ethanol activated 322 HSPB1 release from hepatocytes, we performed *in vitro* studies of ethanol challenge using 323 hepatocyte cell lines. 324 Ethanol exposure rapidly and robustly increased HSPB1 protein in HepG2 cells, even before 325 HSPB1 mRNA levels increased (Fig. 4A, B, C). This type of rapid upregulation without the 326 need for increased transcription has been reported for heat shock proteins, including HSPB1 with 327 other types of cell stress.<sup>44, 45</sup> It also fits with the extensively documented roles that HSPB1 plays 328 in cellular survival during many different types of stress, including oxidative stress. Since our 329 primary interest in hepatocyte produced HSPB1 was in HSPB1 release from hepatocytes, we 330 investigated whether ethanol challenge led to increased amounts of HSPB1 in the hepatocyte 331 media. Exposure to ethanol led to an approximately 3-fold increase in extracellular HSPB1 332 within 1 hr. (Fig. 4D). This increase was triggered in response to ethanol metabolism, not cell 333 membrane damage, since inhibiting ethanol metabolism with 4-methylpyrazole (4-MP) 334 completely eliminated HSPB1 release in response to ethanol challenge (Fig. 4E, F). We 335 performed these experiments in two hepatocyte cell lines, HepG2 (human) and AML12 (murine), 336 to account for any cell-line related effects on ethanol metabolism or HSPB1 production and 337 release. Thus, ethanol metabolism leads to rapid increases in both intracellular HSPB1 and

338 HSPB1 released from hepatocytes.





#### 341 Figure 4. HSPB1 is increased in EtOH-stressed hepatocytes and released into the

#### 342 extracellular environment.

343 A, Immunoblotting for HSBP1 and GAPDH in HepG2 cells exposed to vehicle control or 2.5 mM (1.5%) EtOH for

1 hr. **B**, Intracellular HSPB1 concentration measured in cell lysates of HepG2 cells exposed to vehicle control or 2.5

345 mM EtOH for 1 hr. by ELISA. C, HSPB1 gene expression relative to GAPDH in HepG2 cells exposed to vehicle

346 control or 2.5 mM EtOH for 1 hr. by qRT-PCR. **D**, Extracellular HSPB1 concentration measured in culture media

from HepG2 cells exposed to vehicle control or 2.5 mM EtOH for 1 hr. by ELISA. E, Extracellular HSPB1

348 concentration measured in cell media from HepG2 cells exposed to vehicle control, 5 mM 4MP, 2.5 mM EtOH, or

349 2.5 mM EtOH and 5 mM 4MP for 1 hr. by ELISA. F, Extracellular HSPB1 concentration measured in cell media

from AML12 cells exposed to vehicle control, 5 mM 4MP, 2.5 mM EtOH, or 2.5 mM EtOH and 5 mM 4MP for 1

hr. by ELISA. Data are plotted as mean ± SD. B, C, D. Unpaired T-test. E, F. One-way ANOVA with a Tukey's

352 multiple comparisons post-hoc test. n.s. P > 0.05, \*  $P \le 0.05$ , \*\*  $P \le 0.01$ , \*\*\*  $P \le 0.001$ , \*\*\*\*  $P \le 0.0001$ .

353

#### 354 HSPB1 released from ethanol stressed hepatocytes promotes liver-damaging inflammation.

355 In the extracellular environment, HSPB1 functions as a DAMP to amplify macrophage

356 inflammatory responses, including those involving  $TNF\alpha$ .<sup>32, 33</sup>  $TNF\alpha$  is of particular interest


357 since it has been implicated in liver damage and hepatocyte death in patients with AH.<sup>46</sup> This

- 358 cytokine is also reportedly increased in plasma from liver disease patients with elevated HSPB1
- 359 in circulating lymphomonocytes.<sup>47</sup> Despite minimal changes to the hepatic parenchyma in our

EtOH mice receiving the Lieber-DeCarli diet, there was a higher level of TNF $\alpha$  in the liver of these mice than Pair controls (**Fig. 5A**). Furthermore, the level of TNF $\alpha$  was related to the level of HSPB1 in the liver in these mice (**Fig. 5B**).

363 Macrophages are the primary producers of pro-inflammatory cytokines, including TNF $\alpha$  in the ethanol-stressed liver.<sup>12</sup> Our finding that ethanol stress triggers HSPB1 release from 364 365 hepatocytes led us to consider that extracellular HSPB1 could act on nearby macrophages to 366 amplify TNF $\alpha$  secretion during CAC. As previously reported, ethanol robustly increased TNF $\alpha$ secretion by macrophages within one hour of exposure (Fig. 5C).<sup>48</sup> In contrast, TNFa secretion 367 368 was unchanged in HSPB1 treated macrophages at 1 hour. However, at 24 hours, TNFα secretion 369 was significantly increased in HSPB1 treated macrophages and levels were essentially identical 370 to ethanol-exposed macrophages (Fig. 5D). The combination of HSPB1 and ethanol increased 371 TNF $\alpha$  release slightly over each component alone. These data suggest that the mechanisms and 372 kinetics of TNFa secretion elicited by HSPB1 and ethanol differ, but not the inflammatory 373 outcome. They also demonstrate that macrophages need never encounter ethanol or MAMPs 374 directly to activate inflammation during CAC. HSPB1 is sufficient to activate TNFa mediated 375 inflammation and has the potential to amplify inflammation triggered by either ethanol or 376 MAMPs.

377 We next investigated whether blocking extracellular HSPB1 is sufficient to inhibit TNF $\alpha$ 378 release from macrophages exposed to ethanol stressed hepatocytes. Media conditioned by 379 ethanol stressed HepG2 cells was used to replicate the natural form and amount of HSPB1 380 released from hepatocytes in these experiments. We added anti-HSPB1 antibody to the 381 hepatocyte conditioned media, then added the treated media to macrophages, and measured 382 TNF $\alpha$  release. The addition of anti-HSPB1 antibody reduced TNF $\alpha$  release from macrophages 383 significantly (Fig. 5E). Overall, our data suggest that HSPB1 is an important initiator of TNF $\alpha$ 384 dependent inflammation and hepatocyte death in AH. They also show that anti-HSPB1 antibody 385 is a rational therapeutic strategy to protect the ethanol stressed liver.



388 Figure 5. Extracellular HSPB1 promotes liver-damaging inflammation.

- A, TNFα concentration in liver lysates from of Pair and EtOH mice measured by ELISA. B, Linear regression
  analysis of liver HSPB1 and TNFα in Pair and EtOH mice. C, TNFα concentration measured in RAW264.7 cells
  after 1 hr. of treatment with 3 µM HSPB1, 2.5 mM (1.5%) EtOH, or both 2.5 mM EtOH and 3 µM HSPB1 by
  ELISA. D, TNFα concentration measured in RAW264.7 cells after 24 hr. of treatment with 3 µM HSPB1, 2.5 mM
- 393 EtOH, or both 2.5 mM EtOH and 3 μM HSPB1 by ELISA. E, TNFα concentration in RAW264.7 cells after
- 394 exposure to EtOH stressed HepG2 (2.5 mM EtOH for 24 hr.) conditioned media with or with or without 2.5 mg/ml
- 395 anti-HSPB1 antibody measured by ELISA. Data are plotted as mean ± SD. A. Unpaired T-test. B. Simple Linear
- 396 Regression. C, D, E. One-ANOVA with a Tukey's multiple comparisons post-hoc test. n.s. P > 0.05, \* $P \le 0.05$ , \*\*
- $397 \qquad P \le 0.01, *** P \le 0.001, **** P \le 0.0001.$
- 398

387

#### 399 **DISCUSSION**

400 Inflammation destabilizes ALD, leading to disease progression and AH. In this study, we 401 discovered that HSPB1 is increased in the liver and blood of patients with severe AH. We also

402 demonstrated that HSPB1 is released from ethanol stressed hepatocytes and triggers 403 inflammation linked with progression to AH and increased mortality in ALD. Extracellular 404 HSPB1 has been identified as a DAMP in published literature. For example, cardiomyocytes 405 subjected to ischemia and reperfusion injury have been shown to release HSPB1 to activate toll like receptor 2/4 on endothelial cells.<sup>49</sup> Extracellular HSPB1 is also reported to trigger TNFa 406 407 inflammation in macrophages.<sup>32, 33</sup> Our work shows that HSPB1 fits the classical profile of a 408 DAMP in ALD, in that it activates macrophages when released from ethanol stressed cells. 409 However, it is unlike many other DAMPs, in that it normally present at low levels and is rapidly 410 increased in response to ethanol. In CAC, this means that it is released from cells that have 411 encountered ethanol or evidence of ethanol toxicity (i.e., MAMPs) and upregulated HSPB1. 412 Release of DAMPs is generally considered to be a product of dead cells.<sup>15</sup> However, there is 413 ample evidence that HSPB1 is secreted by live cells, including hepatocytes.<sup>29, 50</sup>

414 This work not only adds HSPB1 to the list of DAMPs identified in ALD, it also demonstrates 415 that this protein is a cause of TNF $\alpha$  mediated inflammation associated with the progression to 416 AH. Inflammation was established as a therapeutic target in AH decades ago.<sup>51</sup> Since that time, 417 preclinical and clinical studies have identified inflammatory pathways and mediators that 418 contribute to liver damage and hepatocyte death. The cytokine  $TNF\alpha$  is among the inflammatory 419 mediators most strongly linked to AH. Patients with AH have higher levels of  $TNF\alpha$  in their 420 blood than healthy controls and TNF $\alpha$  is increased in the liver of animals chronically consuming ethanol versus control animals.<sup>52-54</sup> At the cellular level, ethanol stabilizes TNFa mRNA in 421 macrophages, leading to rapid increases in TNFa production and release from these cells.<sup>48, 55, 56</sup> 422 Macrophages also produce  $TNF\alpha$  in response to MAMPs and DAMPs that are increased in 423 424 CAC.<sup>57</sup> Alcohol increases MAMP delivery to the liver by damaging the intestinal epithelium and allowing translocation across the gut mucosal barrier.<sup>58</sup> Alcohol also increases DAMPs in the 425 liver due to secretion from stressed cells and release from dead or dying cells.<sup>15</sup> The high level of 426 427 TNFα generated in these conditions activates programmed cell death in hepatocytes both *in vitro* 428 and *in vivo*.<sup>46, 59</sup> In pre-clinical models, TNF receptor 1 knockout or anti-TNFα antibody protect animals from liver damage.<sup>54, 60</sup> However, clinical studies of anti-TNFa antibodies were halted 429 early due to life-threatening infections in the AH patients.<sup>61, 62</sup> This highlights the importance of 430 431 targeting liver damaging "sterile inflammation" while leaving host defense intact in AH.

432 The first step in targeting liver damaging sterile inflammation is identifying appropriate 433 therapeutic targets and biomarkers for those targets. Our findings suggest that HSPB1 is a 434 component of sterile inflammation in AH and therefore warrants further investigation as a 435 biomarker and/or therapeutic target in this disease. HSPB1 fits several criteria for these 436 applications: 1) Differences in HSPB1 can be measured in the blood. 2) HSPB1 is significantly 437 higher in AH than other forms of liver disease and increases with increasing disease severity. 3) 438 HSPB1 is upstream of liver-damaging inflammation and so potentially indicates risk for 439 inflammation before it occurs. 4) Blocking HSPB1 action blocks TNFa mediated inflammation 440 in vitro.

441 HSPB1 has already been proposed as a biomarker for disease severity in cancers, most notably hepatocellular carcinoma (HCC).<sup>27</sup> In HCC, HSPB1 is increased in lymphomonocytes 442 and tumor tissue, especially in cases associated with a history of alcohol use.<sup>28, 47</sup> High levels of 443 444 liver HSPB1 have also been associated with increased immune cell infiltration into tumor tissue 445 and worse prognosis in HCC.<sup>27, 28</sup> Alcohol-associated liver diseases have also been linked to naturally occurring anti-HSPB1 antibodies.<sup>25</sup> These antibodies could be important both 446 447 diagnostically and therapeutically. Concern has been raised that anti-HSPB1 antibodies could interfere with measurement of HSPB1 in standard, ELISA-based assays.<sup>31</sup> Additionally, 448 449 naturally occurring anti-HSPB1 antibodies could influence HSPB1 functions and/or interfere 450 with antibody-based therapeutics directed at HSPB1. Here, we utilized a commercially available 451 ELISA, and results supported that this assay is able to measure the form and amount of HSPB1 452 released from ethanol stressed cells. We did not measure anti-HSPB1 antibodies in our patient 453 population due to limited sample volume and this limitation also precluded any investigation of 454 effects of naturally occurring anti-HSPB1 antibody on extracellular HSPB1 functions. These 455 types of studies will need to be performed in the future if HSPB1 is developed as a therapeutic 456 target for AH.

457 Development of HSPB1 as a biomarker for AH will also require prospective studies that 458 measure HSPB1 concentration throughout the course of disease. High levels of HSPB1 may 459 predict which patients are at highest risk for disease exacerbation and most in need of intense 460 monitoring or early liver transplantation. Conversely, low HSPB1 may be useful to stratify 461 patients into a low-risk group, since HSPB1 was no different in our patients consuming large

amounts of alcohol without liver disease and healthy controls. Multiple timepoint sampling
would reveal whether a single cut-off value of HSPB1 or changing levels of circulating HSPB1
would be most useful clinically.

465 Aside from its potential to serve as a biomarker in ALD, HSPB1 also shows promise as a 466 therapeutic target in the inflammation of AH. Our data show that HSPB1 is upstream of  $TNF\alpha$ 467 mediated inflammation. Extracellular HSPB1 has also been reported to activate a second 468 macrophage inflammatory mediator implicated in AH, IL-1B. Therefore, targeting HSPB1 has 469 the potential to block activation of multiple inflammatory pathways and broadly protect 470 hepatocytes from inflammation activated cell death programs. Our work specifically 471 demonstrates the potential efficacy of an anti-HSPB1 antibody to interrupt inflammation in AH. 472 We would expect this type of agent to be particularly effective at blocking the DAMP function of 473 HSPB1, while leaving intracellular, cytoprotective functions of HSPB1 intact. It would also 474 preserve TNF $\alpha$  activation by microbes and allow TNF $\alpha$  mediated inflammation in host defense 475 mounted by macrophages.

476 Together, our findings directly link HSPB1 to inflammation in AH and provide a potential 477 explanation for disease exacerbation. We propose that HSPB1 is highly upregulated in 478 hepatocytes in response to ethanol metabolism and released into the extracellular environment 479 where it activates TNF $\alpha$  in macrophages. When ethanol exposure is limited in amount or 480 duration, we presume that HSPB1 is both cytoprotective in hepatocytes and promotes tissue 481 repair through activation of low levels of TNF $\alpha$  at the site of damage. Conversely, when ethanol 482 exposure occurs at high levels or is sustained for long periods of time, the high levels of  $TNF\alpha$ 483 could overwhelm HSPB1 cryoprotection, leading to hepatocyte death. Additionally, the dying 484 ethanol stressed hepatocytes would be expected to release high levels of HSPB1, which would 485 amplify TNF $\alpha$  production and causes even more hepatocyte death leading to a feed-forward or 486 vicious cycle. Our data support this model in a number of ways. However, several key questions 487 do remain unanswered. First, does extracellular HSPB1 act on cells other than macrophages 488 during CAC? Hepatic stellate cells and other infiltrating innate and adaptive immune cells could 489 also be influenced by HSPB1 to contribute to disease. Second, does anti-HSPB1 antibody inhibit 490 inflammation in the complex context of the intact liver during CAC? To answer this question, we 491 need to test our anti-HSPB1 antibody in an animal model that mimics more severe, inflammatory

492 ALD. This experiment would also reveal any negative effects of anti-HSPB1 antibody on 493 hepatocyte health in this context. Lastly, which inflammatory pathways does extracellular 494 HSPB1 activate in the liver during CAC? We focused on TNF $\alpha$  in this study due to its strong 495 link to AH, but HSPB1 likely also activates IL-1ß and potentially other pro-inflammatory 496 cytokines in CAC. Answering these questions could lead to novel diagnostic and therapeutic 497 approaches to ALD based on targeting HSPB1. This type of strategy could identify patients at 498 risk of severe inflammatory liver disease and short-circuit inflammation to protect the liver 499 against life-threatening injury.

500

## 501 MATERIALS AND METHODS

#### 502 Human subjects

503 Study protocols were approved by the Institutional Review Boards (IRB) at the Cleveland 504 Clinic and MetroHealth Hospitals. All procedures were performed according to the IRB 505 guidelines and all subjects provided written informed consent.

506

507 Human serum samples. Enrolled patients had confirmed diagnosis of ALD by clinicians based on 508 medical history, physical examination, and laboratory results, according to the guidelines of the 509 American College of Gastroenterology (https://gi.org/clinical-guidelines/). Healthy controls 510 (HC) were recruited from the Clinical Research Unit at the Cleveland Clinic. Serum was 511 collected in gold top tubes and allowed to clot for 30 minutes at room temperature. Samples were 512 then centrifuged for 10 minutes at 4°C. Aliquots were frozen at -80°C until use. Descriptive 513 demographic and clinical data from these patients are provided in Tables 1-3. 514 Human liver samples. Healthy control and alcohol-associated hepatitis liver samples were 515 516 provided by the NIAAA R24 Clinical Resource for Alcohol-associated Hepatitis Investigations

517 at Johns Hopkins University. The resource provided liver from 5 patients with severe AH and 5

518 healthy donors that was obtained during liver transplantation. Tissues were snap frozen in liquid

519 nitrogen and stored at -80°C prior to use. Descriptive demographic and clinical data from these

520 patients are provided in Table 4.

Human liver RNA-seq data and analysis. RNA transcipts were obtained from the InTEAM
Consortium – Alcoholic Hepatitis dbGaP Study, Accession phs001807.v1.p1. Transcripts per
million (TPMs) for visualization were calculated as follows. Raw counts were normalized by
dividing the counts by the length of each gene in kilobases to obtain reads per kilobases (RPK).
The total RPK values in a sample were summed and then divided by 1,000,000 to give the "per
million" scaling factor. Log2 fold changes were calculated by running raw counts through the
DESeq2 pipline in R (v 4.2.2).

529

# 530 Animal studies

531 All animal protocols were approved by the Cleveland Clinic Institutional Animal Care and 532 Use Committee. Mice used in this study were C57BL/6 mice (Strain 000664) purchased from Jackson Laboratories and maintained under specific pathogen free (SPF) conditions. Mice were 533 534 allowed to acclimate to the Cleveland Clinic animal facility for 5 days prior to the start of 535 studies. All animal experiments were performed two independent times using female mice 536 between 6 and 12 weeks of age. Female mice were chosen because of published data 537 demonstrating that ALD is more severe in female mice and humans. Mice were housed under a 538 12-hour light/dark cycle in shoe-box cages (2 animals/cage) with microisolator lids and fed 539 standard laboratory chow. Standard microisolator handling procedures were used throughout the 540 study.

541 Lieber-DeCarli Diet model of chronic alcohol consumption. Mice were randomized into ethanol-

542 fed (EtOH) and pair-fed (Pair/Control) groups and then adapted to the base liquid diet (Dyets,

543 Bethlehem, PA; 710260) for 2 days. The EtOH group was then allowed free access to the base

544 diet that contained increasing concentrations of EtOH over time: 1% and 2% (vol/vol) each for

545 2 days, then 4 and 5% EtOH each for 7 days, and finally 6% EtOH for another 7 days. The 6%

546 (vol/vol) diet provided EOH as 32% of total calories in the diet. Control mice were pair-fed diets

547 which isocalorically substituted maltodextrin for EtOH over the entire feeding period. At the end

of the study, mice were anesthetized, blood samples were obtained from the posterior vena cava

549 using nonheparinized syringes, livers were excised, and the mice were euthanized by

550 exsanguination.

- 551 *Mouse liver protein isolation.* Snap frozen liver sections were placed into microcentrifuge tubes
- 552 with 400 μL of tissue lysis buffer (Cell Signaling, 9803S) supplemented with protease inhibitor
- 553 (Roche, 11836170001) and placed on ice. Livers were homogenized using a Tissue-Tearor.
- 554 Protein concentration was determined by BCA (Pierce, 23228).
- 555

#### 556 Cell culture studies

All cell lines were obtained directly from American Type Culture Collection (ATCC) or
 from the Cleveland Clinic Cell Culture Core which obtained them directly from ATCC. Cell
 phenotypes were routinely monitored, and cells were periodically tested for mycoplasma
 contamination.

561 HSPB1 recombinant protein. HEK293 cells were transfected with an endotoxin-free prep 562 (Takara Bio, 740426.50) of HSPB1-FLAG DNA (Genecopoeia, EX-I0586-M39) using TransIT-563 293 (Mirus Bio, MIR2705) according to the manufacturer's protocol. Cells were transfected for 564 72 hours, then lysate was collected in TBS + 1 mM DTT supplemented with 1x Protease 565 Inhibitor Cocktail (Roche, 11836170001). Lysates were sonicated on ice (1 min total time on; 10 566 seconds on/10 seconds off; Amp= 30%) and centrifuged at 15,000 x G for 20 min at 4 °C. The 567 supernatant was then dialyzed overnight into TBS + 0.15 M NaCl, pH 7. The dialyzed 568 supernatant was then directly applied onto 1mL bed of pre-equilibrated ANTI-FLAG® M2 569 Affinity Gel resin (Sigma, A2220). After allowing the protein to bind by gravity flow, the 570 column was washed with 15 column volumes of TBS. HSPB1-FLAG was eluted by pouring five 571 1 bed volumes worth of 0.1M Glycine-HCl, pH 3.5. Five elution fractions were collected in 5 572 sequential 1.5 mL microcentrifuge tubes, each containing 50 µl of 0.1M Tris pH 8.0 to neutralize 573 acid. Elution fractions were pooled together and spun down in 10 kDa spin concentrator to 574 increase concentration, then buffer exchanged into HEPES storage buffer. Protein was then 575 stored at 4°C.

- 576 *Ethanol stress in hepatocytes.* HepG2 hepatocytes were seeded into a 6-well tissue culture plate 577 at 250,000 cells per well. The following day, the media was removed from the wells and the cells 578 were treated with either 500  $\mu$ L of 2.5 mM (1.5%) ethanol in serum-free EMEM or 500  $\mu$ L 579 serum-free EMEM for 1 hour at 37°C and 5% CO<sub>2</sub>. After ethanol stress, the supernatant was
- 580 removed from the cells and frozen at -80°C until use. The cells were then scraped off the plate

581 with a disposable cell scraper into 300  $\mu$ L of PBS, pipetted up and down to homogenize lysate, 582 and then frozen at -80°C until use.

583

*Hepatocytes stressed with ethanol in the presence of 4-methylpyrazole (4-MP).* HepG2 or AML12 hepatocytes were seeded into a 6-well tissue culture plate at 250,000 cells per well. The following day, the media was removed from the wells, and the cells were treated with 500 μL of 2.5 mM (1.5%) ethanol in serum-free EMEM, 5 mM 4MP in 500 μL of serum-free EMEM, or 500 μL serum-free EMEM for 1 hour at 37°C and 5% CO<sub>2</sub>. After incubation, the supernatant was removed from the cells and frozen at -80°C until use. The cells were then scraped off the plate with a disposable cell scraper into 300 μL of PBS, pipetted up and down to homogenize lysate,

and then frozen at -80°C until use.

592

593 Ethanol stress in macrophages treated with recombinant human HSPB1. RAW264.7

594 macrophages were seeded into a 6-well tissue culture plate at 250,000 cells per well. The 595 following day, the media was removed from the wells and the cells were treated with 500  $\mu$ L of 596 2.5 mM (1.5%) ethanol in serum-free DMEM, 3  $\mu$ M HSPB1 in 500  $\mu$ L of serum-free DMEM, 3 597  $\mu$ M HSPB1, and 2.5 mM ethanol in serum-free DMEM, or 500  $\mu$ L of DMEM for 1 hour or 24 598 hours at 37°C and 5% CO<sub>2</sub>.

599

600 Macrophages exposed to media conditioned by ethanol stressed hepatocytes and treated with 601 anti-HSPB1 antibody. Two T75 tissue culture flasks containing HepG2 hepatocytes (~70-80% 602 confluent) were treated with 10 mL of serum-free DMEM or 10 mL of serum-free DMEM 603 containing 2.5 mM (1.5%) ethanol for 24 hours at 37°C and 5% CO<sub>2</sub>. The conditioned media was 604 then removed from the culture flasks and split in half. Half of the media was used as a control 605 and the other half was incubated with 2.5 mg/mL anti-HSPB1 antibody (Custom antibody 606 produced by Biomatik). Both control and antibody treated media samples were rotated overnight 607 at 4°C. RAW264.7 macrophages were plated the day prior to conditioned media collection at 608 250,000 cells per well in a 6 well tissue culture dish in DMEM supplemented with 10% FBS. 609 After preparation of the treated and control conditioned media, the complete media was removed 610 from the RAW264.7 cells. The RAW264.7 cells were then treated with 500  $\mu$ L of serum-free 611 DMEM (negative experimental control), serum-free DMEM with 2.5mM ethanol (positive

- 612 experimental control), non-ethanol treated HepG2 conditioned media, non-ethanol treated
- 613 HepG2 conditioned media with anti-HSPB1 antibody, ethanol treated HepG2 conditioned media,
- or ethanol treated HepG2 conditioned media with anti-HSPB1 antibody for 1 hour at 37°C and
- 615 5% CO<sub>2</sub>.
- 616

#### 617 HSPB1 assays

- 618 HSPB1 and phosphorylated-HSPB1 in human serum by ELISA. For measurement of HSPB1,
- 619 serum samples were diluted 1:4 in reagent diluent and the ELISA completed per the
- 620 manufacture's protocol (R&D, DY1580). For measurement of phosphorylated-HSPB1
- 621 (S78/S82), serum samples were diluted 1:2 in reagent diluent and the ELISA completed per the
- 622 manufacture's protocol (R&D, DYC2314-2).
- 623

624 HSPB1 in murine liver by ELISA. 100 µL of lysate (normalized by protein concentration) was 625 loaded in triplicate onto a high-binding polystyrene plate (Costar, 07-200-39) and incubated 626 overnight at 4°C. The following day, lysate was decanted, and the plate washed once with 200 627 µL per well of PBS with 0.01% Tween-20. The plate was blocked using 1% BSA in PBS (200 628 µL per well) for 1.5 hours at room temperature. After blocking, 50 µL of 0.63 mg/mL anti-629 HSPB1 antibody (Biomatik) was added to the plate and incubated for 2 hours at room 630 temperature. After primary antibody incubation, the plate was washed 3 times with 200 µL of 631 PBS with 0.01% Tween-20 per well. Then 50 µL of secondary antibody conjugated with 632 horseradish peroxidase (Jackson Immunoresearch, 711-035-152) was added to the plate at a final 633 concentration of 0.08 mg/mL for 1 hour. The plate was then again washed 3 times with PBS with 634 0.01% Tween-20 and 50 µL of pre-warmed TMB was added to the plate. The detection reagent 635 was developed for 5 minutes at room temperature and then the reaction was quenched with 50 636  $\mu$ L of 0.5M sulfuric acid. The plate was then read at 450<sub>nm</sub> on a spectrophotometer (Synergy). 637 638 *qRT-PCR for HSPB1 in murine liver*. Total RNA was isolated from snap frozen liver samples by 639 Trizol:chloroform extraction as per the manufacturer's protocol (Invitrogen, 15596026), then 640 precipitated using glycoblue, 3M sodium acetate and isopropanol. After washing twice with 80%

- 641 ethanol, the RNA pellet was resuspended in nuclease free water and further purified using an
- 642 RNA Clean and Concentrate column as per manufacturer protocol (Zymo Research, R1013). 1

643 mg of total RNA per sample was reverse transcribed (SuperScript IV Reverse Transcriptase,

oligo dT primers, ThermoFisher, 18091050), and quantitative PCR performed on a QuantStudio

645 6 Flex Real-Time PCR System (Applied Biosystems) using TaqMan Fast Advanced Master Mix

646 (Applied Biosystems, 4444557) and TaqMan probes for *Hspb1* (ThermoFisher,

647 MM00834384\_G1) and *Gapdh* (ThermoFisher, MM99999915\_G1). *Hspb1* transcript levels were

648 normalized to *Gapdh* and fold changes were calculated using the delta-delta CT method.

649

650 *qRT-PCR for HSPB1 in HepG2 cells*. At the end of experiments described above, media was

651 removed from the cells, and cells were gently rinsed once with 500  $\mu$ L of DPBS (Dubucco's

652 phosphate buffered saline, Genesee, 25-508). DPBS was removed and 200 μL of RNAlater

653 (Invitrogen, AM7020) was added to each well. Cells were scraped off and collected into a

654 microcentrifuge tube. RNA was isolated using PureLink RNA mini kit (Ambion, 12-183-018A)

655 per the manufacturer's instructions. 1 mg of total RNA per sample was reverse transcribed

656 (Applied Biosystems, 43-688-14) and quantitative PCR performed on a CFX96 Touch Real-

657 Time PCR system (Bio-Rad). Primer sequences: Hspb1 Forward -

658 5'AAGCTAGCCACGCAGTCCAA3'; *Hspb1* Reverse -5'CGACTCGAAGGTGACTGGGA3';

659 Gapdh Forward -5'TGGTATCGTGGAAGGACTCATGAC3'; Gapdh Reverse -

660 5'ATGCCAGTGAGCTTCCCGTTCAGC3'. Transcript levels were normalized to Gapdh and

fold changes were calculated using the delta-delta CT method.

662

663 Immunostaining for HSPB1 in murine liver. Formalin-fixed paraffin embedded liver was sliced 664 into 5 µm sections and placed on glass slides. The slides were heated to 60°C on a heat block for 665 30 minutes and then submerged 3 times for 5 minutes in xylene. The slides were then rehydrated 666 by submerging them 30 times in 95% ethanol followed by 15 submersions in 70% ethanol, and 667 finally, submersion for 1 minute in deionized water. Slides were washed 2 times in TBS with 668 0.01% Tween-20 for 5 minutes and then underwent antigen retrieval by steaming submerged in 669 sodium citrate for 20 minutes followed by a 1-hour cooling period. After steaming, a 670 hydrophobic border was drawn around the tissue with a PAP pen and slides were blocked with 671 Superior blocking buffer (G-Biosciences, 786-660) for 1 hour at room temperature. Anti-HSPB1 672 antibody (Biomatik) was added to the slides at a final concentration of 1.26 mg/mL and left to 673 incubate overnight at 4°C in a humid chamber. The following day, slides were washed for 15

674 minutes total in TBS with 0.01% Tween-20. Anti-rabbit Alexa Fluor 647 conjugated secondary 675 antibody was added to the slides at a final concentration of 0.9 mg/mL and incubated for 30 676 minutes at room temperature protected from light (protection from light continued from this 677 point forward). Slides were washed again for 15 minutes total in TBS with 0.01% Tween-20 and 678 then counterstained with 10 mg/mL bisBenzimide H (Sigma-Aldrich, 33258) dissolved in TBS 679 for 20 minutes at room temperature. Finally, slides were washed for 5 minutes with deionized 680 water and cover slipped. All immunofluorescent sections were imaged using either a widefield 681 fluorescent microscope (Keyence BZ-800) or an inverted confocal microscope (40x/1.25 oil 682 objective on a Leica TCS-SP8-AOBS inverted confocal microscope (Leica Microsystems, 683 GmbH, Wetzlar, Germany)). 684

*HSPB1 in hepatocytes by ELISA*. Cell culture media or cell lysates were thawed on ice and then
normalized to protein content by BCA assay (Pierce, 23228). HSPB1 concentration was
measured in human cells (HepG2) with the R&D Human HSP27 DuoSet ELISA kit (DY1580)
according to the manufacturer's protocol. HSPB1 concentration was measured in murine cells
(AML12) using the same protocol described for the murine liver samples.

690

691 *Immunoblotting for HSPB1*. Cell or liver lysates were boiled in Laemmli buffer containing 10% 692 b-mercaptoethanol for 10 minutes. SDS-PAGE Gel electrophoresis was performed using 12% 693 NuPage Bis-Tris gels with MOPS buffers. Proteins were transferred to PVDF membranes and 694 blocked with LiCOR Intercept PBS blocking buffer (LiCor, 927-70003) for 1 hour. Membranes 695 were then incubated in blocking buffer containing 0.63 mg/mL anti-HSPB1 antibody (Biomatik) 696 and 0.282 mg/mL anti-GAPDH antibody (Cell Signaling, D4C6R) overnight at 4°C with 697 agitation. The membranes were washed 3 times with PBS with 0.01% Tween-20 for 5 minutes 698 each wash and then incubated with 0.2 mg/mL 680RD (LI-COR, 926-68023) anti-rabbit or 0.2 699 mg/mL 800RD (LI-COR, 926-32212) anti-mouse secondary antibody in blocking buffer for one 700 hour. Membranes were then again washed 3 times with PBS with 0.01% Tween-20 for 5 minutes 701 and fluorescent signal was detected using an LI-COR Odyssey CLX machine and LI-COR 702 Acquisition software. Densitometry was performed using ImageJ.

703

704 Other assays

705 Liver Triglycerides. Measured pieces of liver (80-85mg) were digested in 3 M KOH at 70°C for 706 1 hour then left overnight at room temperature. The next day the total volume was brought to 707 500 µL with 2M Tris-HCl pH 7.5 and then diluted 1:5 with 2M Tris-HCl pH 7.5. 10 µL of 708 diluted sample was added to of 1 mL of pre-warmed GPO triglyceride reagent (Pointe Scientific 709 Inc., T7532-500). After a 5-minute incubation, samples were read on a spectrophotometer at 500 710 nm. 711 712 Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT). For both assays, murine 713 serum was thawed on ice. For AST, 5  $\mu$ L serum was added to 100  $\mu$ L of AST reagent (Sekisui 714 Diagnostics, 319-30) and read on a spectrophotometer at 340nm every 30 seconds for 20 715 minutes. For ALT, 10 µL serum was added to 90 µL of ALT reagent (Sekisui Diagnostics, 318-716 30) and read on a spectrophotometer at 340nm every 30 seconds for 30 minutes. 717 718  $TNF\alpha$  ELISA in cell culture supernatants. At the end of experiments described above, cell media 719 was collected and TNF $\alpha$  concentrations measured using the Mouse TNF-alpha Quantikine 720 ELISA Kit (R&D, #MTA00B) according to manufacturer's protocol and recommendations. 721 722 **Statistics** 723 Values shown in all figures represent the means  $\pm$  SD, except figures 2C, D, and E which 724 represent the means  $\pm$  SEM. Pairwise differences were evaluated using parametric or non-725 parametric two-tailed t-tests as appropriate. Differences among multiple groups was detected 726 using one-way ANOVAs with post-hoc analysis. Statistical analysis was performed using 727 GraphPad Prism (v.10.2.2), except analysis in figures 2C-E, which was performed using R (v 728 4.2.2). A P value of less than 0.05 was considered significant. 729 730 731 732

#### 733 **REFERENCES**

- Alcohol-induced Death Rates in the United States, 2019–2020. Hyattsville, MD:
   https://dx.doi.org/10.15620/cdc:121795, 2022.
- Niu X, Zhu L, Xu Y, et al. Global prevalence, incidence, and outcomes of alcohol related
  liver diseases: a systematic review and meta-analysis. BMC Public Health 2023;23:859.
- 738 3. Centers for Disease Control and Prevention. Alcohol Related Disease Impact (ARDI)
- application, 2024. www.cdc.gov/ARDI, 2024.
- Cholankeril G, Ahmed A. Alcoholic Liver Disease Replaces Hepatitis C Virus Infection
  as the Leading Indication for Liver Transplantation in the United States. Clin
  Gastroenterol Hepatol 2018;16:1356-1358.
- 5. Dang K, Hirode G, Singal AK, et al. Alcoholic Liver Disease Epidemiology in the United
  States: A Retrospective Analysis of 3 US Databases. Am J Gastroenterol 2020;115:96104.
- Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-Associated
  Liver Disease. Official journal of the American College of Gastroenterology | ACG
  2024;119:30-54.
- 749 7. Rachakonda V, Bataller R, Duarte-Rojo A. Recent advances in alcoholic hepatitis.
  750 F1000Res 2020;9.
- 751 8. Yamazaki T, Schnabl B. Acute alcohol-associated hepatitis: Latest findings in non752 invasive biomarkers and treatment. Liver International 2023;n/a.
- 753 9. Mackowiak B, Fu Y, Maccioni L, et al. Alcohol-associated liver disease. J Clin Invest
  754 2024;134.
- Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from
  pathogenesis to novel therapeutic strategies. Cell Mol Immunol 2016;13:316-27.
- Wen Y, Lambrecht J, Ju C, et al. Hepatic macrophages in liver homeostasis and diseasesdiversity, plasticity and therapeutic opportunities. Cellular & Molecular Immunology
  2021:18:45-56.
- Ju C, Mandrekar P. Macrophages and Alcohol-Related Liver Inflammation. Alcohol Res
  2015;37:251-62.
- 762 13. Wang HJ, Gao B, Zakhari S, et al. Inflammation in alcoholic liver disease. Annu Rev
  763 Nutr 2012;32:343-68.

Kubes P, Mehal WZ. Sterile Inflammation in the Liver. Gastroenterology

764

14.

765 2012;143:1158-1172. 766 15. Han H, Desert R, Das S, et al. Danger signals in liver injury and restoration of 767 homeostasis. J Hepatol 2020;73:933-951. 768 16. Kojima K, Musch MW, Ropeleski MJ, et al. Escherichia coli LPS induces heat shock 769 protein 25 in intestinal epithelial cells through MAP kinase activation. Am J Physiol 770 Gastrointest Liver Physiol 2004;286:G645-52. 771 17. Petrof EO, Musch MW, Ciancio M, et al. Flagellin is required for salmonella-induced 772 expression of heat shock protein Hsp25 in intestinal epithelium. Am J Physiol 773 Gastrointest Liver Physiol 2008;294:G808-18. 774 18. Wang N, Liu X, Liu K, et al. Homo-oxidized HSPB1 protects H9c2 cells against 775 oxidative stress via activation of KEAP1/NRF2 signaling pathway. iScience 776 2023;26:107443. 777 19. Arrigo AP. Mammalian HspB1 (Hsp27) is a molecular sensor linked to the physiology 778 and environment of the cell. Cell Stress Chaperones 2017;22:517-529. 779 20. Acunzo J, Katsogiannou M, Rocchi P. Small heat shock proteins HSP27 (HspB1), αB-780 crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int J Biochem Cell 781 Biol 2012;44:1622-31. 782 21. Tan HK, Yates E, Lilly K, et al. Oxidative stress in alcohol-related liver disease. World J 783 Hepatol 2020;12:332-349. 784 22. Paul C, Simon S, Gibert B, et al. Dynamic processes that reflect anti-apoptotic strategies 785 set up by HspB1 (Hsp27). Exp Cell Res 2010;316:1535-52. 786 23. Pignataro L, Varodayan FP, Tannenholz LE, et al. Brief alcohol exposure alters 787 transcription in astrocytes via the heat shock pathway. Brain Behav 2013;3:114-33. 24. 788 Feng JT, Liu YK, Song HY, et al. Heat-shock protein 27: a potential biomarker for 789 hepatocellular carcinoma identified by serum proteome analysis. Proteomics 790 2005;5:4581-8. 791 25. Gruden G, Carucci P, Barutta F, et al. Serum levels of anti-heat shock protein 27 792 antibodies in patients with chronic liver disease. Cell Stress Chaperones 2021;26:151-793 157.

794	26.	Gruden G, Carucci P, Lolli V, et al. Serum heat shock protein 27 levels in patients with
795		hepatocellular carcinoma. Cell Stress Chaperones 2013;18:235-41.
796	27.	Liang C, Xu Y, Ge H, et al. The clinicopathological and prognostic value of HSP27 in
797		hepatocellular carcinoma: a systematic review and meta-analysis. Onco Targets Ther
798		2018;11:1293-1303.
799	28.	Long S, Peng F, Song B, et al. Heat Shock Protein Beta 1 is a Prognostic Biomarker and
800		Correlated with Immune Infiltrates in Hepatocellular Carcinoma. Int J Gen Med
801		2021;14:5483-5492.
802	29.	De Maio A, Cauvi DM, Capone R, et al. The small heat shock proteins, HSPB1 and
803		HSPB5, interact differently with lipid membranes. Cell Stress Chaperones 2019;24:947-
804		956.
805	30.	Yang F, Beltran-Lobo P, Sung K, et al. Reactive astrocytes secrete the chaperone HSPB1
806		to mediate neuroprotection. Sci Adv 2024;10:eadk9884.
807	31.	Batulan Z, Pulakazhi Venu VK, Li Y, et al. Extracellular Release and Signaling by Heat
808		Shock Protein 27: Role in Modifying Vascular Inflammation. Front Immunol 2016;7:285.
809	32.	Salari S, Seibert T, Chen YX, et al. Extracellular HSP27 acts as a signaling molecule to
810		activate NF-kB in macrophages. Cell Stress Chaperones 2013;18:53-63.
811	33.	Ogbodo E, Michelangeli F, Williams JHH. Exogenous heat shock proteins HSPA1A and
812		HSPB1 regulate TNF- $\alpha$ , IL-1 $\beta$ and IL-10 secretion from monocytic cells. FEBS Open
813		Bio 2023;13:1922-1940.
814	34.	Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases,
815		functions and pathology. Cell Mol Life Sci 2009;66:3289-307.
816	35.	Hyun J, Han J, Lee C, et al. Pathophysiological Aspects of Alcohol Metabolism in the
817		Liver. Int J Mol Sci 2021;22.
818	36.	Zou Y, Shi H, Liu N, et al. Mechanistic insights into heat shock protein 27, a potential
819		therapeutic target for cardiovascular diseases. Front Cardiovasc Med 2023;10:1195464.
820	37.	Sookoian S, Castaño GO, Scian R, et al. Heat Shock Protein 27 is down-regulated in
821		Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH). Sci Rep
822		2016;6:22528.

823	38.	Bălănescu A, Bălănescu PC, Codreanu IF, et al. Exploring the Role of Serum Osteonectin
824		and Hsp27 in Pediatric MAFLD Diagnosis and Cardiometabolic Health. Nutrients
825		2024;16.
826	39.	Guo F, Zheng K, Benedé-Ubieto R, et al. The Lieber-DeCarli Diet-A Flagship Model for
827		Experimental Alcoholic Liver Disease. Alcohol Clin Exp Res 2018;42:1828-1840.
828	40.	Gao B, Ahmad MF, Nagy LE, et al. Inflammatory pathways in alcoholic steatohepatitis. J
829		Hepatol 2019;70:249-259.
830	41.	Liu J. Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty
831		liver. World J Gastroenterol 2014;20:14672-85.
832	42.	Cunningham RP, Porat-Shliom N. Liver Zonation - Revisiting Old Questions With New
833		Technologies. Front Physiol 2021;12:732929.
834	43.	Kammoun M, Picard B, Astruc T, et al. The Invalidation of HspB1 Gene in Mouse Alters
835		the Ultrastructural Phenotype of Muscles. PLoS One 2016;11:e0158644.
836	44.	Alagar Boopathy LR, Jacob-Tomas S, Alecki C, et al. Mechanisms tailoring the
837		expression of heat shock proteins to proteostasis challenges. J Biol Chem
838		2022;298:101796.
839	45.	Rini DM, Yamamoto Y, Suzuki T. Partially hydrolyzed guar gum upregulates heat shock
840		protein 27 in intestinal Caco-2 cells and mouse intestine via mTOR and ERK signaling. J
841		Sci Food Agric 2023;103:5165-5170.
842	46.	Tiegs G, Horst AK. TNF in the liver: targeting a central player in inflammation. Semin
843		Immunopathol 2022;44:445-459.
844	47.	Federico A, Tuccillo C, Terracciano F, et al. Heat shock protein 27 expression in patients
845		with chronic liver damage. Immunobiology 2005;209:729-35.
846	48.	Nagy LE. Stabilization of tumor necrosis factor-alpha mRNA in macrophages in response
847		to chronic ethanol exposure. Alcohol 2004;33:229-33.
848	49.	Jin C, Cleveland JC, Ao L, et al. Human myocardium releases heat shock protein 27
849		(HSP27) after global ischemia: the proinflammatory effect of extracellular HSP27
850		through toll-like receptor (TLR)-2 and TLR4. Mol Med 2014;20:280-9.
851	50.	Giuliano JS, Jr., Lahni PM, Wong HR, et al. Pediatric Sepsis - Part V: Extracellular Heat
852		Shock Proteins: Alarmins for the Host Immune System. Open Inflamm J 2011;4:49-60.

853	51.	Feng D, Hwang S, Guillot A, et al. Inflammation in Alcohol-Associated Hepatitis:
854		Pathogenesis and Therapeutic Targets. Cell Mol Gastroenterol Hepatol 2024;18:101352.
855	52.	Bird GL, Sheron N, Goka AK, et al. Increased plasma tumor necrosis factor in severe
856		alcoholic hepatitis. Ann Intern Med 1990;112:917-20.
857	53.	Khoruts A, Stahnke L, McClain CJ, et al. Circulating tumor necrosis factor, interleukin-1
858		and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-
859		76.
860	54.	Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor $\alpha$ in alcohol-
861		induced liver injury in mice. Gastroenterology 1999;117:942-952.
862	55.	Kishore R, McMullen MR, Nagy LE. Stabilization of tumor necrosis factor alpha mRNA
863		by chronic ethanol: role of A + U-rich elements and p38 mitogen-activated protein kinase
864		signaling pathway. J Biol Chem 2001;276:41930-7.
865	56.	McMullen MR, Cocuzzi E, Hatzoglou M, et al. Chronic ethanol exposure increases the
866		binding of HuR to the TNFalpha 3'-untranslated region in macrophages. J Biol Chem
867		2003;278:38333-41.
868	57.	Sun J, Zhao P, Shi Y, et al. Recent insight into the role of macrophage in alcohol-
869		associated liver disease: a mini-review. Front Cell Dev Biol 2023;11:1292016.
870	58.	Bishehsari F, Magno E, Swanson G, et al. Alcohol and Gut-Derived Inflammation.
871		Alcohol Res 2017;38:163-171.
872	59.	van Loo G, Bertrand MJM. Death by TNF: a road to inflammation. Nat Rev Immunol
873		2023;23:289-303.
874	60.	Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa
875		attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the
876		rat. Hepatology 1997;26:1530-7.
877	61.	Blendis L, Dotan I. Anti-TNF therapy for severe acute alcoholic hepatitis: What went
878		wrong? Gastroenterology 2004;127:1637-1639.
879	62.	Boetticher NC, Peine CJ, Kwo P, et al. A Randomized, Double-Blinded, Placebo-
880		Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis.
881		Gastroenterology 2008;135:1953-1960.
882		